Relationship between adiponectin and leptin, and blood lipids in hyperlipidemia patients treated with red yeast rice

Forschende Komplementarmedizin

Volumn 20, Issue 3, 2013, Pages 197-203

  Lee, Chien Ying ^a,b   Jan, Ming Shiou ^b   Yu, Min Chien ^a,b   Lin, Chun Che ^a,b   Wei, James Cheng Chung ^a,b,c   Shih, Hung Che ^a,b  

^a CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^b CHUNG SHAN MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^c CHINA MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Adiponectin; HDL C; High density lipoprotein cholesterol; LDL C; Leptin; Low density lipoprotein cholesterol; Red yeast rice

Indexed keywords

4 AMINOBUTYRIC ACID; ADIPONECTIN; BIOLOGICAL PRODUCT; CHOLESTEROL; CHOLESTIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LEPTIN; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN;

ADULT; ARTICLE; BLOOD; BODY MASS; CHINESE MEDICINE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET SUPPLEMENTATION; DRUG COMBINATION; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; INTENTION TO TREAT ANALYSIS; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADIPONECTIN; ADULT; BIOLOGICAL PRODUCTS; BODY MASS INDEX; CHOLESTEROL; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DIETARY SUPPLEMENTS; DRUG COMBINATIONS; FEMALE; GAMMA-AMINOBUTYRIC ACID; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; INTENTION TO TREAT ANALYSIS; LEPTIN; LIPIDS; LOVASTATIN; MALE; MEDICINE, CHINESE TRADITIONAL; MIDDLE AGED; TREATMENT OUTCOME;

EID: 84880763029     PISSN: 16614119     EISSN: 16614127     Source Type: Journal    
DOI: 10.1159/000351455     Document Type: Article

References (41)

1. Berliner JA, Navab M, Fogelman AM, et al.: Atherosclerosis: basic mechanisms. Oxidation, inflammation, and genetics. Circulation 1995;91: 2488-2496.
2. Smith SC Jr, Benjamin EJ, Bonow RO, et al.: AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation. Circulation 2011;124: 2458-2473.
3. Reiner Z, Catapano AL, De Backer G, et al.: ESC/ EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 2011;32: 1769-1818.
4. No authors listed: Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-1389.
5. Eisenberg DM, Davis RB, Ettner SL, et al.: Trends in alternative medicine use in the United States, 1990-1997: results of a follow-up national survey. JAMA 1998;280: 1569-1575.
6. Patrick L, Uzick M: Cardiovascular disease: Creactive protein and the inflammatory disease paradigm: HMG-CoA reductase inhibitors, alphatocopherol, red yeast rice, and olive oil polyphenols. A review of the literature. Altern Med Rev 2001;6: 248-271.
7. Smith DJ, Olive KE: Chinese red rice-induced myopathy. South Med J 2003;96: 1265-1267.
8. Lau DC, Dhillon B, Yan H, Szmitko PE, Verma S: Adipokines: molecular links between obesity and atheroslcerosis. Am J Physiol Heart Circ Physiol 2005;288: H2031-2041.
9. Brennan AM, Mantzoros CS: Drug Insight: the role of leptin in human physiology and pathophysiology -emerging clinical applications. Nat Clin Pract Endocrinol Metab 2006;2: 318-327.
10. Lindsay RS, Funahashi T, Hanson RL, et al.: Adiponectin and development of type 2 diabetes in the Pima Indian population. Lancet 2002;360: 57-58.
11. Arita Y, Kihara S, Ouchi N, et al.: Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 1999; 257: 79-83.
12. Shepherd J, Cobbe SM, Ford I, et al.: Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995;333: 1301-1307.
13. Lin LY, Liau CS, Yang WS, Su TC: Decreased serum adiponectin in adolescents and young adults with familial primary hypercholesterolemia. Lipids 2005;40: 163-167.
14. Ben Ounis O, Elloumi M, Ben Chiekh I, Zbidi A, Amri N, Lac G, Tabka Z: Effects of two-month physical- endurance and diet-restriction programmes on lipid profiles and insulin resistance in obese adolescent boys. Diabetes Metab 2008;34: 595-600.
15. Kontush A, Chapman MJ: Functionally defective high-density lipoprotein: a new therapeutic target at the crossroads of dyslipidemia, inflammation, and atherosclerosis. Pharmacol Rev 2006;58: 342-374.
16. Bjorbaek C, Kahn BB: Leptin signaling in the central nervous system and the periphery. Recent Prog Horm Res 2004;59: 305-331.
17. Becker DJ, Gordon RY, Halbert SC, French B, Morris PB, Rader DJ: Red yeast rice for dyslipidemia in statin-intolerant patients: a randomized trial. Ann Intern Med 2009;150: 830-839, W147-839.
18. Journoud M, Jones PJ: Red yeast rice: a new hypolipidemic drug. Life Sci 2004;74: 2675-2683.
19. Huang CF, Li TC, Lin CC, Liu CS, Shih HC, Lai MM: Efficacy of Monascus purpureus Went rice on lowering lipid ratios in hypercholesterolemic patients. Eur J Cardiovasc Prev Rehabil 2007;14: 438-440.
20. Endo A: Monacolin K, a new hypocholesterolemic agent produced by a Monascus species. J Antibiot (Tokyo) 1979;32: 852-854.
21. Vandenberg BF, Robinson J: Management of the patient with statin intolerance. Curr Atheroscler Rep 2010;12: 48-57.
22. Kadowaki T, Yamauchi T: Adiponectin and adiponectin receptors. Endocr Rev 2005;26: 439-451.
23. Mantzoros CS, Li T, Manson JE, Meigs JB, Hu FB: Circulating adiponectin levels are associated with better glycemic control, more favorable lipid profile, and reduced inflammation in women with type 2 diabetes. J Clin Endocrinol Metab 2005;90: 4542-4548.
24. Snijder MB, Heine RJ, Seidell JC, et al.: Associations of adiponectin levels with incident impaired glucose metabolism and type 2 diabetes in older men and women: the hoorn study. Diabetes Care 2006;29: 2498-2503.
25. Aprahamian TR, Sam F: Adiponectin in cardiovascular inflammation and obesity. Int J Inflam 2011;2011: 376909.
26. Verges B, Petit JM, Duvillard L, Dautin G, Florentin E, Galland F, Gambert P: Adiponectin is an important determinant of apoA-I catabolism. Arterioscler Thromb Vasc Biol 2006;26: 1364-1369.
27. Chen K, Li F, Li J, et al.: Induction of leptin resistance through direct interaction of C-reactive protein with leptin. Nat Med 2006;12: 425-432.
28. Soderberg S, Ahren B, Jansson JH, Johnson O, Hallmans G, Asplund K, Olsson T: Leptin is associated with increased risk of myocardial infarction. J Intern Med 1999;246: 409-418.
29. Farooqi IS, Matarese G, Lord GM, et al.: Beneficial effects of leptin on obesity, T cell hyporesponsiveness, and neuroendocrine/metabolic dysfunction of human congenital leptin deficiency. J Clin Invest 2002;110: 1093-1103.
30. Brennan AM, Li TY, Kelesidis I, Gavrila A, Hu FB, Mantzoros CS: Circulating leptin levels are not associated with cardiovascular morbidity and mortality in women with diabetes: a prospective cohort study. Diabetologia 2007;50: 1178-1185.
31. Cnop M, Havel PJ, Utzschneider KM, et al.: Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins: evidence for independent roles of age and sex. Diabetologia 2003;46: 459-469.
32. WHO Expert Consultation: Appropriate body mass index for Asian populations and its implications for policy and intervention strategies. Lancet 2004; 363: 157-163.
33. Banerji MA, Faridi N, Atluri R, Chaiken RL, Lebovitz HE: Body composition, visceral fat, leptin, and insulin resistance in Asian Indian men. J Clin Endocrinol Metab 1999;84: 137-144.
34. Matsubara M, Maruoka S, Katayose S: Inverse relationship between plasma adiponectin and leptin concentrations in normal-weight and obese women. Eur J Endocrinol 2002;147: 173-180.
35. Yang WS, Lee WJ, Funahashi T, et al.: Weight reduction increases plasma levels of an adiposederived anti-inflammatory protein, adiponectin. J Clin Endocrinol Metab 2001;86: 3815-3819.
36. Perez-Matute P, Martinez JA, Marti A, Moreno-Aliaga MJ: Linoleic acid decreases leptin and adiponectin secretion from primary rat adipocytes in the presence of insulin. Lipids 2007;42: 913-920.
37. Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, Pratley RE, Tataranni PA: Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 2001;86: 1930-1935.
38. Pelleymounter MA, Cullen MJ, Baker MB, Hecht R, Winters D, Boone T, Collins F: Effects of the obese gene product on body weight regulation in ob/ob mice. Science 1995;269: 540-543.
39. Havel PJ, Kasim-Karakas S, Mueller W, Johnson PR, Gingerich RL, Stern JS: Relationship of plasma leptin to plasma insulin and adiposity in normal weight and overweight women: effects of dietary fat content and sustained weight loss. J Clin Endocrinol Metab 1996;81: 4406-4413.
40. Klein S, Coppack SW, Mohamed-Ali V, Landt M: Adipose tissue leptin production and plasma leptin kinetics in humans. Diabetes 1996;45: 984-987.
41. Toornvliet AC, Pijl H, Frolich M, Westendorp RG, Meinders AE: Insulin and leptin concentrations in obese humans during long-term weight loss. Neth J Med 1997;51: 96-102.